Henry Chan

Title: Innovations by Henry Chan

Introduction

Henry Chan is a notable inventor based in Poway, California, with a remarkable portfolio of six patents. His work primarily focuses on advancements in antibody engineering, particularly in the context of cancer treatment.

Latest Patents

One of his latest patents involves the engineering of an antibody for tumor-selective binding of CD47. This invention provides antibodies that comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor-associated antigen (TAA) CD20. The Fab portion that binds CD47 exhibits low affinity for CD47, while the Fab portion that binds CD20 exhibits high affinity for CD20. This antibody selectively binds CD47 and blocks its interaction with SIRPα in tumor cells, exhibiting no substantial binding to CD47 in normal cells. Another significant patent is related to SIRP-α binding proteins and methods of use thereof. This patent provides compositions, methods, and uses involving antibodies that specifically bind to signal regulatory protein-α (SIRPα) and modulate its activity.

Career Highlights

Henry Chan is currently associated with Celgene Corporation, where he contributes to innovative research and development in the field of biotechnology. His expertise in antibody engineering has positioned him as a key player in the fight against cancer.

Collaborations

Henry has collaborated with notable colleagues such as Kandasamy Hariharan and Jeonghoon Sun, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Henry Chan's contributions to the field of antibody engineering exemplify the innovative spirit of modern science. His patents reflect a commitment to advancing cancer treatment and improving patient outcomes.